Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 edges lower as financials drag

Thu, 11th Apr 2024 17:13

Lok'nStore surges to all-time high after buyout by Shurgard

*

AstraZeneca to raise annual dividend for 2024, shares up

*

FTSE 100 down 0.5%, FTSE 250 off 0.1%

April 11 (Reuters) -

The UK's FTSE 100 edged lower on Thursday as investors awaited Britain's economic figures for hints on the path of domestic monetary policy after the European Central Bank (ECB) signalled it may soon start to cut rates.

The blue-chip FTSE 100 closed down 0.5%.

British banking and insurance stocks fell the most, echoing a weak mood among European financial stocks after the ECB

held

rates at a record high as expected but pointed to rate cuts commencing soon.

The UK banks index fell 2.7%, recording its biggest percentage drop in almost two months.

Several heavyweights including Aviva, Lloyds Banking Group and Reckitt Benckiser also fell as they traded without entitlement for dividend.

"While inflation in other parts of the world has been surprising to the downside, U.S. inflation seems to be accelerating, and the question of who will ease policies first remains a key concern," Alejandra Grindal, chief economist at Ned Davis Research, said.

"The positive news is that equities have, on average, shown similar gains a year after the first rate cut, regardless of whether it was initiated by the Fed or another central bank."

Global equity markets have been choppy this week as investors pondered the outlook for global rates after hotter-than-expected U.S. inflation data tempered expectations the Federal Reserve would cut rates several times this year.

Eyes will be on Friday's UK GDP figures as well as inflation and labour market data that could shape expectations around when the Bank of England (BoE) will start cutting rates.

Traders are currently pricing interest rate cuts of 43 basis points from the BoE by the end of 2024, and see the first cut coming in August.

In corporate updates, Darktrace surged 6.3% after the cybersecurity company raised its annual revenue and margin forecasts for the third time this year.

Lok'NStore jumped 16.4% to an all-time high after rival Shurgard agreed to acquire the self-storage company in a deal valued at 378 million pounds ($474 million).

AstraZeneca gained 2.1% after the drugmaker said it intends to increase annual dividend for 2024, betting on strong performance and cash generation. (Reporting by Pranav Kashyap in Bengaluru; Editing by Shounak Dasgupta, Varun H K and Andrew Heavens)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.